E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer

  • Authors:
    • Yu-Xiang Liang
    • Jian-Ming Lu
    • Ru-Jun Mo
    • Hui-Chan He
    • Jian Xie
    • Fu-Neng Jiang
    • Zhuo-Yuan Lin
    • Yan-Ru Chen
    • Yong-Ding Wu
    • Hong-Wei Luo
    • Zheng Luo
    • Wei-De Zhong
  • View Affiliations

  • Published online on: January 29, 2016     https://doi.org/10.3892/ijo.2016.3364
  • Pages: 1650-1658
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Increased expression of E2F1 has been reported to be associated with tumor growth and cell survival of prostate cancer (PCa). However, its roles and mechanisms on PCa have not been fully elucidated. The present study found that E2F1 overexpression in PCa tissues was significantly associated with high Gleason score (P=0.01) and advanced pathological stage (P=0.02). In addition, PCa patients with high E2F1 expression more frequently had shorter biochemical recurrence-free survival (P=0.047) than those with low E2F1 expression. Then, we confirmed that the knock-down of E2F1 expression was able to inhibit cell cycle progression, invasion and migration of PCa cell lines in vitro, along with tumor xenograft growth and epithelial-to-mesenchymal transition (EMT) in vivo. Moreover, we identified CD147 as a novel interaction partner for E2F1 through bio-informatic binding site prediction, combined with chromatin immunoprecipitation-PCR (ChIP-PCR) and western blot analysis. Taken together, our data delineate an as yet unrecognized function of E2F1 as enhancer of tumor invasion and migration of PCa via regulating the expression of CD147 in PCa. Importantly, E2F1 may function as a biomarker that can differentiate patients with biochemical recurrent and non-biochemical recurrent disease following radical prostatectomy, highlighting its potential as a therapeutic target.

References

1 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Nandana S and Chung LW: Prostate cancer progression and metastasis: Potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol. 2:92–101. 2014.PubMed/NCBI

3 

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI and Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 169:517–523. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 101:811–816. 2004. View Article : Google Scholar : PubMed/NCBI

5 

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D and Chen MH: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 21:2163–2172. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Ogawa H, Ishiguro K, Gaubatz S, Livingston DM and Nakatani Y: A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science. 296:1132–1136. 2002. View Article : Google Scholar : PubMed/NCBI

7 

Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M and Nevins JR: Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol. 21:4684–4699. 2001. View Article : Google Scholar : PubMed/NCBI

8 

Ginsberg D: E2F1 pathways to apoptosis. FEBS Lett. 529:122–125. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Johnson DG: The paradox of E2F1: Oncogene and tumor suppressor gene. Mol Carcinog. 27:151–157. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E and Look AT: Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics. 25:130–138. 1995. View Article : Google Scholar : PubMed/NCBI

11 

Montenegro MF, Collado-González MM, Fernández-Pérez MP, Hammouda MB, Tolordava L, Gamkrelidze M and Rodríguez-López JN: Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells. BMC Cancer. 14:5392014. View Article : Google Scholar

12 

Lu M, Liu Z, Yu H, Wang LE, Li G, Sturgis EM, Johnson DG and Wei Q: Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck. Mol Carcinog. 51(Suppl 1): E132–E141. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Rizwani W, Schaal C, Kunigal S, Coppola D and Chellappan S: Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One. 9:e1008882014. View Article : Google Scholar : PubMed/NCBI

14 

Hung JJ, Hsueh CT, Chen KH, Hsu WH and Wu YC: Clinical significance of E2F1 protein expression in non-small cell lung cancer. Exp Hematol Oncol. 1:182012. View Article : Google Scholar : PubMed/NCBI

15 

Ren Z, Kang W, Wang L, Sun B, Ma J, Zheng C, Sun J, Tian Z, Yang X and Xiao W: E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-κB modulation. Mol Cancer. 13:842014. View Article : Google Scholar

16 

Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA and Day ML: Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66:11897–11906. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Zheng C, Ren Z, Wang H, Zhang W, Kalvakolanu DV, Tian Z and Xiao W: E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res. 69:2324–2331. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Libertini SJ, Tepper CG, Guadalupe M, Lu Y, Asmuth DM and Mudryj M: E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. Prostate. 66:70–81. 2006. View Article : Google Scholar

19 

Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, Fu X, Dai QS, Cai C, Chen JH, et al: MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 135:541–550. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, Zhou L, Fu H, Bi XC, He HC, et al: CC chemokine ligand 18 correlates with malignant progression of prostate cancer. Biomed Res Int. 2014:2301832014.PubMed/NCBI

21 

Kwon AT, Arenillas DJ, Worsley Hunt R and Wasserman WW: oPOSSUM-3: Advanced analysis of regulatory motif over-representation across genes or ChIP-Seq datasets. G3 (Bethesda). 2:987–1002. 2012. View Article : Google Scholar

22 

Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM and Messeguer X: Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31:3651–3653. 2003. View Article : Google Scholar : PubMed/NCBI

23 

Zhong WD, Liang YX, Lin SX, Li L, He HC, Bi XC, Han ZD, Dai QS, Ye YK, Chen QB, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer. 130:300–308. 2012. View Article : Google Scholar

24 

Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY and Yuan H: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 14:2762014. View Article : Google Scholar : PubMed/NCBI

25 

Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W, Zhang P, Song E, Huang Q, Ai Q, et al: Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS One. 8:e734362013. View Article : Google Scholar : PubMed/NCBI

26 

Engelmann D, Mayoli-Nüssle D, Mayrhofer C, Fürst K, Alla V, Stoll A, Spitschak A, Abshagen K, Vollmar B, Ran S, et al: E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. J Mol Cell Biol. 5:391–403. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, et al: Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res. 14:82–88. 2008. View Article : Google Scholar : PubMed/NCBI

28 

Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, et al: Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Exp Mol Pathol. 95:227–234. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, et al: Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 11:3122011. View Article : Google Scholar : PubMed/NCBI

30 

Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, et al: CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology. 75:230–236. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Chen ZN, et al: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res. 15:369–374. 2009. View Article : Google Scholar

Related Articles

Journal Cover

April 2016
Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liang, Y., Lu, J., Mo, R., He, H., Xie, J., Jiang, F. ... Zhong, W. (2016). E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer. International Journal of Oncology, 48, 1650-1658. https://doi.org/10.3892/ijo.2016.3364
MLA
Liang, Y., Lu, J., Mo, R., He, H., Xie, J., Jiang, F., Lin, Z., Chen, Y., Wu, Y., Luo, H., Luo, Z., Zhong, W."E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer". International Journal of Oncology 48.4 (2016): 1650-1658.
Chicago
Liang, Y., Lu, J., Mo, R., He, H., Xie, J., Jiang, F., Lin, Z., Chen, Y., Wu, Y., Luo, H., Luo, Z., Zhong, W."E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer". International Journal of Oncology 48, no. 4 (2016): 1650-1658. https://doi.org/10.3892/ijo.2016.3364